Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Feb 23, 2023 5:30pm
207 Views
Post# 35302093

RE:RE:RE:"impressive, paradigm shifting, photodynamic therapy"

RE:RE:RE:"impressive, paradigm shifting, photodynamic therapy"If we don't get accelerated approval I think Dr. Uddin's timeline is reasonable.

It all depends on how many patients are treated every month. If we (optimistically) treat 5 patients a month we might be finished all the primary treatments by the end of 2023. It will take another 450 days to do all the evaluations which brings us to April 2025. Another 3 months to compile and submit the data brings us to July 2025. Assuming we have breakthrough designation it could take 60 days to get an FDA response, which brings us to September 2025.

If we only treat 3 patients a month we can add another 9 months to that, which takes us to June 2026.
<< Previous
Bullboard Posts
Next >>